NXTSBasic Materials · Agricultural Inputs

NXTS Stock Forecast: Nexentis Technologies, Inc. Price Predictions for 2026-2027

Last close, 4 Nov 2026

$0.56

−2.46% on the day

Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 2 of 100 as at 4 Nov 2026 — in the weakest quartile.

Market cap

$1.4M

Ticker Nerd rank

2/ 100

Median analyst target

—

Analysts covering

—

Revenue$0.0

Operating income−$1.7M

Net income−$11.2M

Free cash flow−$623K

Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown

Total return, dividends reinvested

−11.8%

−62.8%

YTD

−95.3%

−97.5%

From 52W high

−97.6%

From 52W low

+5.9%

$23

52-week range, adjusted closes · the dot is the last close

Ticker Nerd rank

NXTS stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Nexentis Technologies, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 4 Nov 2026

2/ 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size

Revisions

Momentum

Issuance

Accruals

Volatility

Growth

Quality

Value

Size (99): Smaller than most of the companies we track.

Value (0): The shares cost a lot relative to the profits and assets behind them.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

NXTS stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on NXTS, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

NXTS appears in the Radar on the weeks it earns a place.

Market Radar, every Monday: the week's biggest rank moves across ~4,600 US stocks, and the reason for each.
The AI build-out map, free: every AI company we track, part by part, and one part in full with each verdict.

The AI build-out map

PDF

AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and serversIn full
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST

Performance

NXTS vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 4 Nov 2026, Nexentis Technologies, Inc. returned −97.5% against +14.8% for the S&P 500, dividends included.

NXTS vs S&P 500, last 12 monthsTotal return, rebased to 100

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

NXTS analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Fundamentals

Nexentis Technologies, Inc. (NXTS) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation

Trailing P/E: 0.1×
Price / sales: —
Price / book: 0.4×
EV / EBITDA: 1.3×

Growth & margins

Revenue growth (YoY): −100.0%
Earnings growth (YoY): −100.0%
Gross margin: —
Operating margin: 0.0%
Net margin: 0.0%

Returns & dividend

Return on equity: −454.8%
Return on assets: −29.5%
Dividend yield: 0.0%

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Nexentis Technologies, Inc. (NXTS) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

Nexentis Technologies, Inc. has a market value of $1.4M and an enterprise value of −$7.8M.
Revenue in the twelve months to 30 June 2026: −$66K. The latest quarter shrank 100.0% year on year.
Net income over the same four quarters: −$16.1M, a 24454.5% net margin.
Free cash flow in the twelve months to 30 June 2026: −$4.2M.
Shares outstanding: 1.5M.
Trailing P/E: 0.1×.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Nexentis Technologies, Inc. employs 7 people — −$9K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 4 Nov 2026

Data provided by Twelve Data

Peers

NXTS vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelAgricultural Inputs

Company	Market cap	TKN rank
NXTSNexentis Technologies, Inc.	$1.4M	2
SEEDOrigin Agritech Ltd.	$10.2M	20
BIOXBioceres Crop Solutions Corp.	$16.0M	27
AVDAmerican Vanguard Corp.	$27.9M	38
CAPSCapstone Holding Corp.*	$1.9M	31
BGLCBioNexus Gene Lab Corp.*	$2.8M	21
CNEYCN Energy Group, Inc.*	$4.2M	19

* Nearest Basic Materials names by size — few agricultural inputs companies of this scale trade in the US universe.

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Nexentis Technologies, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest NXTS news & analysis

Nexentis: MitoCareX Completes Initial AI-Powered Computational Screening Milestone with Boltz

GlobeNewsWire · 29 Oct 2026positive

MitoCareX completed an initial AI-powered computational screening milestone using Boltz. The company characterized the findings as preliminary and not yet experimentally validated, while noting they are encouraging for further computational analysis and experimental investigation.

Why it matters — The milestone provides NXTS watchers an update on MitoCareX’s research progress, though the findings remain preliminary and unvalidated experimentally.

Nexentis: MitoCareX Bio Advances AI-Driven Drug Discovery Initiative with Boltz, Completing Initial Computational Screening Stage

GlobeNewsWire · 26 Oct 2026positive

MitoCareX Bio completed the initial computational screening stage of its AI-driven drug discovery initiative with Boltz. The company described the preliminary, computational findings as encouraging for further analysis and experimental investigation, while noting they have not been experimentally validated.

Why it matters — NXTS watchers may note progress in a drug-discovery initiative, though the findings remain preliminary and unvalidated experimentally.

Nexentis: MitoCareX Bio Deploys its Computational Drug Discovery Infrastructure on Google Cloud

GlobeNewsWire · 7 Oct 2026positive

MitoCareX Bio deployed its computational drug discovery infrastructure on Google Cloud Platform. The deployment is designed to enhance computational capacity, data governance, and operational flexibility as the company advances its drug discovery programs.

Why it matters — NXTS watchers may note the cloud deployment as an infrastructure development supporting MitoCareX Bio’s drug discovery programs.

Nexentis: MitoCareX Strengthens Its Computational Drug Discovery Capabilities with Appointment of Prof. Dan T. Major to Scientific Advisory Board

GlobeNewsWire · 24 Sept 2026positive

Nexentis Technologies announced that Prof. Dan T. Major, a leading computational chemistry expert, has been appointed to the Scientific Advisory Board of its subsidiary MitoCareX. Prof. Major will advise MitoCareX as it expands its in silico (computational) drug-discovery capabilities.

Why it matters — NXTS watchers may see this appointment as strengthening MitoCareX's computational drug-discovery capabilities, potentially enhancing the company's drug development efforts.

Nexentis: MitoCareX Evaluates Expanded Protein Capabilities to Enhance Flexibility and Support Future Drug Discovery

GlobeNewsWire · 23 Sept 2026positive

MitoCareX is evaluating additional commercially available approaches for obtaining proteins, with the goal of enhancing access to research materials, increasing research flexibility, and supporting the advancement of its future in-vitro drug discovery programs.

Why it matters — A Nexentis watcher would care because expanded protein sourcing capabilities could support the flexibility and future progress of MitoCareX's in-vitro drug discovery programs.

FAQ

Frequently asked questions about NXTS stock

How does Ticker Nerd's model rank NXTS?

As at 4 Nov 2026, Nexentis Technologies, Inc. ranks 2 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (99 of 100).

What is the NXTS stock forecast for 2030?

No analyst covering Nexentis Technologies, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for NXTS are extrapolating price history, which says nothing about the business.

How has NXTS stock performed over the past year?

Nexentis Technologies, Inc. returned -97.5% over the 12 months to 4 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Nexentis Technologies, Inc. do?

What is the latest news on NXTS?

The most recent item we track (GlobeNewsWire, 29 Oct 2026): "Nexentis: MitoCareX Completes Initial AI-Powered Computational Screening Milestone with Boltz". MitoCareX completed an initial AI-powered computational screening milestone using Boltz. The company characterized the findings as preliminary and not yet experimentally validated, while noting they are encouraging for further computational analysis and experimental investigation.

Company

About Nexentis Technologies, Inc.

Nexentis Technologies Inc., through its subsidiary, develops therapeutics related to cancer and inflammatory metabolic diseases. It operates through two segments, Biotechnology Activity and Renewable Energy Projects. The company's pipeline includes MITOLINE, an algorithm used to perform multiple sequence/ structure pairwise alignments which could then be used for generating a 3D comparative model of potentially all mitochondrial carrier proteins; cloud-based computational chemistry platform; and novel in-vitro screening platforms; and advanced 3D NSCLC tumor spheroid systems.The company was formerly known as N2OFF, Inc. and changed its name to Nexentis Technologies Inc. in February 2026. Nexentis Technologies Inc. was incorporated in 2009 and is headquartered in Ness Ziona, Israel.

7 employees · Israel · https://www.nexentistech.com